Reinhard Gabathuler

Summary

Publications

  1. ncbi Blood-brain barrier transport of drugs for the treatment of brain diseases
    Reinhard Gabathuler
    Angiochem Inc, Montreal, Quebec, Canada
    CNS Neurol Disord Drug Targets 8:195-204. 2009
  2. doi Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases
    Reinhard Gabathuler
    Angiochem Inc, Montreal, Quebec, Canada H2X3Y7
    Neurobiol Dis 37:48-57. 2010
  3. doi Transport characteristics of a novel peptide platform for CNS therapeutics
    Yanick Bertrand
    Laboratoire de Medecine Moleculaire, Universite du Quebec a Montreal, Montreal, Canada Angiochem, Inc, Montreal, Canada
    J Cell Mol Med 14:2827-39. 2010
  4. doi Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2
    Michel Demeule
    Angiochem, Montreal, Quebec, Canada
    J Neurochem 106:1534-44. 2008
  5. doi [New protein vectors for physiological transfer of therapeutic agents to the central nervous system]
    Reinhard Gabathuler
    Cydweli Consultants Inc, Quebec, Canada
    Biol Aujourdhui 206:191-203. 2012
  6. ncbi Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier
    Reinhard Gabathuler
    Cydweli Consultants Inc, 201 Chemin du Golf, Suite 702, Montreal, Quebec, H3E 1Z4, Canada
    Ther Deliv 1:571-86. 2010
  7. ncbi Identification and design of peptides as a new drug delivery system for the brain
    Michel Demeule
    Laboratoire de Medecine Moleculaire, Centre d Hémato Oncologie, Hôpital Ste Justine Université du Québec à Montréal, Montreal, QC, Canada
    J Pharmacol Exp Ther 324:1064-72. 2008

Collaborators

  • Herve Sartelet
  • Abedelnasser Abulrob
  • Michel Demeule
  • Yanick Bertrand
  • Richard Beliveau
  • Jean Paul Castaigne
  • Anthony Regina
  • Christian Che
  • Jean Christophe Currie
  • Tran Nguyen
  • Dorothy Fatehi
  • Danica Stanimirovic
  • Julie Poirier

Detail Information

Publications7

  1. ncbi Blood-brain barrier transport of drugs for the treatment of brain diseases
    Reinhard Gabathuler
    Angiochem Inc, Montreal, Quebec, Canada
    CNS Neurol Disord Drug Targets 8:195-204. 2009
    ..As a result, various strategies are being developed to enhance access of drugs to the brain parenchyma at therapeutically meaningful concentrations to effectively manage disease...
  2. doi Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases
    Reinhard Gabathuler
    Angiochem Inc, Montreal, Quebec, Canada H2X3Y7
    Neurobiol Dis 37:48-57. 2010
    ....
  3. doi Transport characteristics of a novel peptide platform for CNS therapeutics
    Yanick Bertrand
    Laboratoire de Medecine Moleculaire, Universite du Quebec a Montreal, Montreal, Canada Angiochem, Inc, Montreal, Canada
    J Cell Mol Med 14:2827-39. 2010
    ..The primary sequence and charge of Angiopep-2 were crucial for its passage across the BBB. Overall, the results demonstrate the significant potential of this platform for the development of novel neurotherapeutics...
  4. doi Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2
    Michel Demeule
    Angiochem, Montreal, Quebec, Canada
    J Neurochem 106:1534-44. 2008
    ..Fluorescent microscopy also revealed that Alexa488-Angiopep-2 co-localized with LRP1 in brain endothelial cell monolayers. Overall, these results suggest that Angiopep-2 transport across the BBB is, in part, mediated by LRP1...
  5. doi [New protein vectors for physiological transfer of therapeutic agents to the central nervous system]
    Reinhard Gabathuler
    Cydweli Consultants Inc, Quebec, Canada
    Biol Aujourdhui 206:191-203. 2012
    ..and is to date the most advanced in human clinical trials, the new Transcend technology using a protein melanotransferrin for the transport of biologics such as lysosomal enzymes and antibodies will be discussed...
  6. ncbi Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier
    Reinhard Gabathuler
    Cydweli Consultants Inc, 201 Chemin du Golf, Suite 702, Montreal, Quebec, H3E 1Z4, Canada
    Ther Deliv 1:571-86. 2010
    ..It is the first of such designed agents to be validated for the treatment of human brain cancers and opens the door for such approaches...
  7. ncbi Identification and design of peptides as a new drug delivery system for the brain
    Michel Demeule
    Laboratoire de Medecine Moleculaire, Centre d Hémato Oncologie, Hôpital Ste Justine Université du Québec à Montréal, Montreal, QC, Canada
    J Pharmacol Exp Ther 324:1064-72. 2008
    ..Overall, these results suggest that these Kunitz-derived peptides could be advantageously used as a new brain delivery system for pharmacological agents that do not readily enter the brain...